June 24, 2022
Indivior, Aquestive and Dr. Reddy's Laboratories have ended their yearslong litigation battle over generic versions of the opioid addiction treatment Suboxone, with the Indian drugmaker on Friday saying it will receive $72 million by April 2024.
August 24, 2020
Dr. Reddy's Laboratories and Alvogen can move forward with antitrust counterclaims against Indivior in a dispute over generic versions of Indivior's opioid addiction treatment Suboxone after a New Jersey federal judge ruled Monday that Indivior was not shielded from liability.
January 25, 2019
Indivior Inc. on Thursday won a bid to temporarily block New Jersey-based Alvogen Pine Brook Inc. from selling a generic version of the opioid addiction treatment drug Suboxone, which is at the center of an ongoing patent row, according to an order from a Garden State federal judge.
August 28, 2018
A New Jersey federal judge on Monday refused to transfer to Delaware a group of Indivior Inc.'s lawsuits that accuse Dr. Reddy's Laboratories, Teva Pharmaceuticals and Alvogen Pine Brook Inc. of pursuing generic versions of brand name opioid addiction treatment drug Suboxone, infringing its patents.